Does Prior Cosentyx Use Affect Flu Shot Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, suppresses parts of the immune system. Studies show it does not significantly impair antibody responses to the inactivated influenza vaccine, even during active treatment. A phase 3b trial in psoriasis patients found seroprotection rates (≥40% antibody rise) of 52-68% post-vaccination with Cosentyx, compared to 64% in placebo—differences not deemed clinically meaningful.[1] Real-world data aligns, with no broad evidence of reduced protection from prior use.
How Long After Stopping Cosentyx Can I Get the Flu Shot?
Cosentyx has a half-life of about 27 days, clearing the body in 4-6 months after the last dose. Immune effects may linger 8-12 weeks post-discontinuation, per EMA labeling.[2] Guidelines from the American College of Rheumatology recommend waiting 1-3 months after stopping biologics like Cosentyx before live vaccines, but inactivated flu shots (standard IM version) pose low risk even sooner—no mandatory wait required. Check with your doctor for personalized timing based on disease control.
What Do Studies Say About Cosentyx and Vaccines?
Key trial (NCT02877182): 243 psoriasis patients on Cosentyx (300mg) got the 2017-18 flu vaccine; geometric mean antibody titers rose comparably to placebo across strains (H1N1, H3N2, B/Victoria, B/Yamagata). No increase in infections reported.[1] Another study in psoriatic arthritis patients confirmed similar seroconversion.[3] Live vaccines (e.g., nasal flu spray) are contraindicated during treatment and for months after due to immunosuppression risks.
Compared to Other Biologics Like Humira or Stelara?
| Drug | Flu Vaccine Impact | Notes |
|------|---------------------|-------|
| Cosentyx (IL-17) | Minimal; good response | Strongest data for flu[1] |
| Humira (TNF) | Mild reduction possible | Variable by study[4] |
| Stelara (IL-12/23) | Comparable to placebo | Safe per trials[5] |
| Dupixent (IL-4/13) | No major effect | Limited flu-specific data |
TNF inhibitors like Humira show slightly more variability, but all are generally safe with inactivated vaccines.
Patient Risks and What to Watch For?
No spike in flu cases linked to Cosentyx-vaccine combos in registries. Still, monitor for breakthrough infections if high-risk (e.g., elderly, comorbidities). CDC advises annual flu shots for all immunosuppressed patients unless contraindicated.[6] Report poor response via VAERS if concerned.
[1]: Efficacy of Influenza Vaccination in Patients With Psoriasis Treated With Secukinumab
[2]: Cosentyx EMA Product Information
[3]: Vaccination Response in Secukinumab-Treated PsA Patients
[4]: ACR Guidelines on Vaccinations in Rheumatic Diseases
[5]: Stelara Vaccine Studies
[6]: CDC Flu Vaccine Recommendations